[go: up one dir, main page]

MX2018008337A - Factor de von willebrand truncado mutado. - Google Patents

Factor de von willebrand truncado mutado.

Info

Publication number
MX2018008337A
MX2018008337A MX2018008337A MX2018008337A MX2018008337A MX 2018008337 A MX2018008337 A MX 2018008337A MX 2018008337 A MX2018008337 A MX 2018008337A MX 2018008337 A MX2018008337 A MX 2018008337A MX 2018008337 A MX2018008337 A MX 2018008337A
Authority
MX
Mexico
Prior art keywords
von willebrand
willebrand factor
truncated von
mutated truncated
seq
Prior art date
Application number
MX2018008337A
Other languages
English (en)
Inventor
Panousis Con
Wilson Michael
Andrews Arna
Emmrich Kerstin
Dower Steve
Hardy Matthew
Hartman Dallas
Original Assignee
CSL Behring Lengnau AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016900034A external-priority patent/AU2016900034A0/en
Application filed by CSL Behring Lengnau AG filed Critical CSL Behring Lengnau AG
Publication of MX2018008337A publication Critical patent/MX2018008337A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención provee un polipéptido modificado que se une al Factor VIII. El polipéptido comprende el Factor de von Willebrand (VWF) truncado que comprende una secuencia como se muestra en SEQ ID NO: 3 o un fragmento de la misma o una secuencia 90% idéntica a la misma, en donde el VWF truncado comprende al menos una modificación en comparación con SEQ ID NO: 3 en al menos una posición seleccionada del grupo que consiste en S1, S3, L18, V42, S43, K149, N248, S279, V320, T325, Q395 y K418.
MX2018008337A 2016-01-07 2017-01-06 Factor de von willebrand truncado mutado. MX2018008337A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2016900034A AU2016900034A0 (en) 2016-01-07 Mutated truncated von willebrand factor
PCT/AU2017/050010 WO2017117631A1 (en) 2016-01-07 2017-01-06 Mutated truncated von willebrand factor

Publications (1)

Publication Number Publication Date
MX2018008337A true MX2018008337A (es) 2018-09-17

Family

ID=59273076

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018008337A MX2018008337A (es) 2016-01-07 2017-01-06 Factor de von willebrand truncado mutado.

Country Status (14)

Country Link
US (1) US10806774B2 (es)
EP (1) EP3400002B1 (es)
JP (1) JP6851381B6 (es)
KR (1) KR20180094114A (es)
CN (1) CN108472338B (es)
AU (1) AU2017204955B2 (es)
BR (1) BR112018013861A2 (es)
CA (1) CA3010720A1 (es)
DK (1) DK3400002T3 (es)
ES (1) ES2909573T3 (es)
MX (1) MX2018008337A (es)
RU (1) RU2018128582A (es)
SG (2) SG10201912498YA (es)
WO (1) WO2017117631A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3008448A1 (en) 2016-01-07 2017-07-13 Csl Behring Recombinant Facility Ag Mutated von willebrand factor
SG10201912360SA (en) * 2016-11-11 2020-02-27 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for treating hemophilia
EP3548066A1 (en) 2016-12-02 2019-10-09 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
BR112019026743A2 (pt) 2017-06-22 2020-06-30 CSL Behring Lengnau AG modulação da imunogenicidade de fviii através de vwf truncado
EP3816181A4 (en) 2018-05-18 2022-04-20 Zhengzhou Gensciences Inc. Improved fviii fusion protein and use thereof
HRP20250709T1 (hr) 2018-05-18 2025-08-15 Bioverativ Therapeutics Inc. Postupci liječenja hemofilije a
US10654911B1 (en) 2019-04-02 2020-05-19 Beijing Neoletix Biological Technology Co., Ltd. Vector co-expressing truncated von Willebrand factor and factor VIII
AU2020300820A1 (en) 2019-07-04 2022-03-03 CSL Behring Lengnau AG A truncated von willebrand factor (vWF) for increasing the in vitro stability of coagulation factor VIII
CN110624105B (zh) * 2019-09-24 2021-06-11 苏州大学 血管性血友病因子的结构敏感多肽抗原的序列
US20220348637A1 (en) * 2019-11-11 2022-11-03 CSL Behring Lengnau AG Polypeptides for inducing tolerance to factor viii

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
US4970300A (en) 1985-02-01 1990-11-13 New York University Modified factor VIII
FR2673632A1 (fr) 1991-03-08 1992-09-11 Lille Transfusion Sanguine Procede de preparation de concentre de facteur von willebrand humain de tres haute purete, approprie a un usage therapeutique.
WO1994015625A1 (en) 1993-01-15 1994-07-21 Enzon, Inc. Factor viii - polymeric conjugates
DE4435485C1 (de) 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
JPH11501506A (ja) 1994-12-12 1999-02-09 ベス イスラエル デアコネス メディカル センター キメラ型サイトカインおよびその利用
WO1997003193A1 (en) 1995-07-11 1997-01-30 Chiron Corporation Novel factor viii:c polypeptide analogs with altered metal-binding properties
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
US20040092442A1 (en) 1996-04-24 2004-05-13 University Of Michigan Inactivation resistant factor VIII
CA2252896C (en) 1996-04-24 2009-03-10 The Regents Of The University Of Michigan Inactivation resistant factor viii
PT1079805E (pt) 1998-04-27 2005-03-31 Opperbas Holding Bv Composicao farmaceutica compreendendo factor viii e lipossomas neutros
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
AU2002248329B2 (en) 2001-01-12 2007-06-28 The American National Red Cross Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor VIII
US7205278B2 (en) 2001-06-14 2007-04-17 The Scripps Research Institute Stabilized proteins with engineered disulfide bonds
US20080108560A1 (en) 2002-03-05 2008-05-08 Eli Lilly And Company Heterologous G-Csf Fusion Proteins
EP1497330B1 (en) 2002-04-29 2010-04-07 Stichting Sanquin Bloedvoorziening Antagonists of factor viii interaction with low-density lipoprotein receptor-related protein
AU2003300276B2 (en) 2002-12-23 2010-07-01 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
US7041635B2 (en) 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
HUE058897T2 (hu) 2003-02-26 2022-09-28 Nektar Therapeutics Polimer VIII-as faktor egység konjugátumok
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
EP3552627A1 (en) 2003-05-06 2019-10-16 Bioverativ Therapeutics Inc. Clotting factor-fc chimeric proteins to treat hemophilia
MXPA05013565A (es) 2003-06-12 2006-03-09 Lilly Co Eli Proteinas de fusion analogas al glp-1.
PT1699821E (pt) 2003-12-31 2012-08-23 Merck Patent Gmbh Proteína de fusão fc-eritropoietina com farmacocinética melhorada
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
ES2821832T3 (es) 2004-11-12 2021-04-27 Bayer Healthcare Llc Modificación de FVIII dirigida al sitio
EP1835938B1 (en) 2004-12-27 2013-08-07 Baxter International Inc. Polymer-von willebrand factor-conjugates
WO2006108590A1 (en) 2005-04-14 2006-10-19 Csl Behring Gmbh Modified coagulation factor viii with enhanced stability and its derivates
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
NZ572050A (en) 2006-03-31 2011-09-30 Baxter Int Factor VIII conjugated to polyethylene glycol
WO2007144173A1 (en) 2006-06-14 2007-12-21 Csl Behring Gmbh Proteolytically cleavable fusion protein comprising a blood coagulation factor
JP5448839B2 (ja) 2006-12-22 2014-03-19 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー インビボで長い半減期を有する修飾された凝固因子
US8173597B2 (en) 2007-11-09 2012-05-08 Baxter International Inc. Modified recombinant factor VIII and von Willebrand factor and methods of use
EP2291523B1 (en) 2008-06-24 2014-12-17 CSL Behring GmbH Factor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life
ES2700230T3 (es) 2009-10-30 2019-02-14 Albumedix Ltd Variantes de albúmina
CA2780542C (en) 2009-11-13 2020-03-24 Grifols Therapeutics Inc. Von willebrand factor (vwf)-containing preparations, and methods, kits, and uses related thereto
CN106977608A (zh) 2010-04-09 2017-07-25 阿尔布麦狄克斯公司 白蛋白衍生物和变体
EP2635598A1 (en) 2010-11-01 2013-09-11 Novozymes Biopharma DK A/S Albumin variants
CN110272484A (zh) 2011-05-05 2019-09-24 阿尔布梅迪克斯医疗有限公司 白蛋白变体
WO2013093760A2 (en) 2011-12-19 2013-06-27 Grifols, S.A. Compositions, methods, and kits for preparing sialylated recombinant proteins
CN109111526A (zh) 2012-01-12 2019-01-01 比奥贝拉蒂治疗公司 嵌合因子viii多肽及其用途
US9458223B2 (en) * 2012-02-15 2016-10-04 Csl Behring Gmbh Von willebrand factor variants having improved factor VIII binding affinity
MX2014010278A (es) 2012-03-16 2015-03-05 Novozymes Biopharma Dk As Variantes de albumina.
JP2015515482A (ja) * 2012-04-24 2015-05-28 ノヴォ ノルディスク アー／エス 血友病の治療に適する化合物
HUE047088T2 (hu) 2012-07-11 2020-04-28 Bioverativ Therapeutics Inc VIII. faktor komplex XTEN-nel és von willebrand-faktor fehérjével, és alkalmazásai
EP2917233A1 (en) 2012-11-08 2015-09-16 Novozymes Biopharma DK A/S Albumin variants
US20160207977A1 (en) 2013-06-12 2016-07-21 Novo Nordisk A/S Compounds Suitable for Treatment of Haemophilia
US10251940B2 (en) 2014-06-06 2019-04-09 Octapharma Ag Preparation comprising factor VIII and Von Willebrand factor peptides
KR20170026580A (ko) 2014-07-02 2017-03-08 씨에스엘 리미티드 변형된 폰 빌레브란트 인자
US10364982B2 (en) * 2015-11-19 2019-07-30 Ansaldo Energia Switzerland AG Method for reconditioning fuel nozzle assemblies
CA3008448A1 (en) 2016-01-07 2017-07-13 Csl Behring Recombinant Facility Ag Mutated von willebrand factor

Also Published As

Publication number Publication date
BR112018013861A2 (pt) 2018-12-18
US20190015483A1 (en) 2019-01-17
EP3400002A1 (en) 2018-11-14
CA3010720A1 (en) 2017-07-13
AU2017204955A1 (en) 2018-07-12
SG10201912498YA (en) 2020-02-27
JP6851381B6 (ja) 2021-04-21
AU2017204955B2 (en) 2021-04-01
DK3400002T3 (da) 2022-04-11
WO2017117631A1 (en) 2017-07-13
CN108472338A (zh) 2018-08-31
EP3400002A4 (en) 2019-07-03
CN108472338B (zh) 2022-12-30
JP2019507587A (ja) 2019-03-22
RU2018128582A (ru) 2020-02-11
EP3400002B1 (en) 2022-02-02
HK1256525A1 (en) 2019-09-27
SG11201805497QA (en) 2018-07-30
JP6851381B2 (ja) 2021-03-31
KR20180094114A (ko) 2018-08-22
US10806774B2 (en) 2020-10-20
ES2909573T3 (es) 2022-05-09

Similar Documents

Publication Publication Date Title
MX2018008337A (es) Factor de von willebrand truncado mutado.
MX2018008293A (es) Factor de von willebrand mutado.
ZA202006432B (en) T cell receptors
AU2017248121A1 (en) T cell receptors
AU2017248120A1 (en) T cell receptors
MX2013004127A (es) Polipeptidos con actividad permeasa.
NZ731571A (en) T cell receptors
NZ600278A (en) Von willebrand factor (vwf)-containing preparations, and methods, kits, and uses related thereto
MX2020005458A (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
WO2020223514A3 (en) Novel omni-50 crispr nuclease
NZ606427A (en) Extended recombinant polypeptides and compositions comprising same
NZ724904A (en) Hybrid immunoglobulin containing non-peptidyl linkage
CY1119916T1 (el) Ανοσογονικη συνθεση
MX393988B (es) Variantes de interferon a2b.
NZ715038A (en) T cell receptors
NO20063026L (no) Antistoffer
BRPI0813003A2 (pt) Promotor
UA108778C2 (xx) Протираковий злитий протеїн
NZ753324A (en) Bivalent antibodies masked by coiled coils
EA202190240A1 (ru) Варианты рекомбинантного белка
HK1215441A1 (zh) 人血清白蛋白结合化合物及其融合蛋白
MY195726A (en) Steviol Glycoside Transport
MX2018003162A (es) Variante en el numero de copias que genera resistencia a virus.
RU2017122029A (ru) Новые способы опосредованного ферментами конъюгирования полипептидов с использованием сортазы
AR101146A1 (es) Proteína con actividad xilanasa

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: CSL BEHRING LENGNAU AG